Security Snapshot

ADARx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ADRX) Institutional Ownership

CUSIP: 00654F105

13F Institutional Holders and Ownership History for Q3 2026

13F reference period

Q3 2026

Institutions Reporting

53

Shares (Excl. Options)

67.42MFull value: 67,421,536 · shares · 30 Sep 2026

Price

$19.94

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+67,396,536
Value change
+$1,339,470,998
Number of holders
53
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
112,510,354
SEC-reported price per share
$17.95
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ADRX - ADARx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 00654F105.
  • 53 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • The headline uses Q3 2026 reported holdings.
  • Quarter-over-quarter comparison is unavailable because the immediately preceding quarter is missing.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 53 institutions filings for Q3 2026.

Open SEC evidence

Security key

00654F105

13F reference period

Q3 2026

13F holders

53

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
ADRX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 14% 14,913,764 ORBIMED ADVISORS LLC 28 Sep 2026
LAV Biosciences Fund V, L.P. 11% $244,762,639 11,858,655 Yi Shi 30 Sep 2026
Li Zhen 9.6% $191,177,594 10,800,994 Zhen Li 30 Sep 2026
SR ONE CAPITAL MANAGEMENT, LLC 9.3% 9,936,661 SR One Capital Management, LLC 28 Sep 2026
BCLS Fund III Investments, LP 6.3% 6,728,970 BCLS Fund III Investments, LP 24 Sep 2026
As of 30 Sep 2026, 53 institutional investors reported holding
67.42MFull value: 67,421,536 · shares · 30 Sep 2026
shares of ADARx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (ADRX). This represents 60% of the company’s total
112.51MFull value: 112,510,354 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
58%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 22% 24,205,789 8.9% $482,663,433
SR ONE CAPITAL MANAGEMENT, LP 8.8% 9,936,661 17% $198,137,020
Bain Capital Life Sciences Investors, LLC 6% 6,728,970 9% $134,175,662
TCG Crossover Management, LLC 3.7% 4,116,452 2.3% $82,082,053
Capital International Investors 1.9% 2,132,301 0.01% $42,518,082
Siren, L.L.C. 1.7% 1,925,794 0.91% $38,400,332
ALLIANCEBERNSTEIN L.P. 1.5% 1,719,816 0.01% $34,293,131
Venrock Adviser, LLC 1.4% 1,625,793 1.6% $32,418,312
T. Rowe Price Investment Management, Inc. 1.4% 1,605,227 0.02% $32,009,000
Woodline Partners LP 1.3% 1,463,478 0.09% $29,181,751
MARSHALL WACE, LLP 1.2% 1,333,496 0.03% $26,589,911
Commodore Capital LP 1.1% 1,260,577 1.9% $25,135,905
Capital World Investors 1.1% 1,200,000 0% $23,928,000
EcoR1 Capital, LLC 1% 1,150,000 1.1% $22,931,000
Cormorant Asset Management, LP 0.86% 962,898 1.3% $19,200,176
Redmile Group, LLC 0.68% 769,345 1.1% $15,340,739
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 0.58% 650,360 0% $12,968,178
GordonMD Global Investments LP 0.4% 450,000 5.9% $8,973,000
Blackstone Inc. 0.37% 421,701 0.03% $8,408,718
RTW INVESTMENTS, LP 0.27% 300,000 0.06% $5,982,000
PERCEPTIVE ADVISORS LLC 0.27% 300,000 0.11% $5,982,000
BRAIDWELL LP 0.27% 300,000 0.25% $5,982,000
Vivo Capital, LLC 0.23% 255,158 0.56% $5,087,851
GOLDMAN SACHS GROUP INC 0.16% 181,300 0% $3,615,122
SEVEN GRAND MANAGERS, LLC 0.13% 149,369 0.12% $2,978,418

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
1
Headline period
Q3 2026
Rows shown
1-1 of 1
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 67,421,536 $1,339,969,498 +$1,339,470,998 $19.94 53
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .